



Hengrui Pharma Partners with Medidata to Accelerate Global Drug Research

November 15, 2018

Leading Sponsor in China to Deliver Innovative Therapies to Patients Worldwide with Medidata Cloud

News summary:

- Hengrui adds Medidata Rave EDC, RTSM, Coder, Safety Gateway and Edge CTMS to support emerging market strategy
- Medidata Cloud enables unified data management for global clinical trial expansion
- One of the largest China-based pharma partners with Medidata to make new global treatment breakthroughs

NEW YORK--(BUSINESS WIRE)--Nov. 15, 2018-- [Medidata](#) (NASDAQ: MDSO) announced that Hengrui Pharma, one of China's largest sponsors, recently adopted Medidata Cloud, the Intelligent Platform for Life Sciences, to accelerate global drug research.

Hengrui selected the Medidata cloud platform in the third quarter of this year to unify data management and navigate international complexities. With Medidata's unrivaled global expertise, the company will:

- Unify clinical trials and reduce risk with a single source for data entry
- Streamline study operations, planning and execution
- Automate reporting of adverse events
- Standardize data on the Medidata Cloud in support of global regulatory compliance requirements

"Medidata will enable us to make a bigger footprint globally and deliver smarter treatments to patients," said Jianjun Zou, chief medical officer, Hengrui Pharma. "Only Medidata's comprehensive offerings can support us as we expand our drug therapies to patients around the world. We are confident that Medidata's exceptional cloud platform and deep understanding of both China and global regions will accelerate our drug development."

Medidata's end-to-end solutions provide a clear view into all clinical trial processes, including study planning and execution. Hengrui, named by [Forbes as one of the 100 most innovative companies](#), will deliver new treatments to patients globally with:

- [Rave EDC](#): the world's leading solution for capturing, managing and reporting patient data
- [Rave RTSM](#): single source of data to improve data quality and risk reduction in randomization and trial supply management
- [Rave Coder](#): cloud application that streamlines and centralizes medical coding
- [Rave Safety Gateway](#): automate adverse events (AEs) and serious adverse events (SAEs) to reduce error and protect patients
- [Edge CTMS](#): modern CTMS system for planning, conducting and monitoring studies

"We are proud to partner with Hengrui Pharma, one of the leading pharma companies in China," said Jim Xu, general manager of Medidata China. "This new relationship further cements our leadership in the region. The Medidata Cloud supports the entire ecosystem of data management, and is why we are uniquely positioned to empower local partners, like Hengrui Pharma, to elevate their clinical research to a higher global standard."

About Medidata

Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181115005471/en/>

Source: Medidata

Medidata:

Investors:

Betsy Frank, +1 917-522-4620

bfrank@mdsol.com

or

Media:

Erik Snider, +1 646-362-2997

esnider@mdsol.com